2024-05-08 21:22:10 ET
CytomX Therapeutics, Inc. (CTMX)
Q1 2024 Results Conference Call
May 08, 2024 05:00 PM ET
Company Participants
Chris Ogden - Senior Vice President, Finance and Accounting
Sean McCarthy - Chief Executive Officer and Chairman
Wayne Chu - Chief Medical Officer
Conference Call Participants
Peter Lawson - Barclays
Roger Song - Jefferies
Joe Catanzaro - Piper Sandler
Etzer Darout - BMO Capital Markets
Anupam Rama - JPMorgan
Mitchell Kapoor - H. C. Wainwright
Presentation
Operator
Good day, and thank you for standing by. Welcome to the CytomX Therapeutics First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only-mode. After the speaker's presentation there will be a question-and-answer session. [Operator Instructions] Please be advised that, today's conference is being recorded.
I would now like to turn the conference over to your speaker today, Chris Ogden, CytomX's Senior Vice President, Finance and Accounting. Please go ahead.
Chris Ogden
Thank you. Good afternoon and thank you for joining us.
Before we begin, I would like to remind everyone that, during this call, we will be making forward-looking statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict and many of which are outside of our control.
Important risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Earlier this afternoon, we issued a press release that includes a summary of our first quarter 2024 financial results and highlights recent progress at CytomX. We also issued a press release today announcing positive initial Phase 1a dose escalation data for monotherapy CX-904 which will be the primary focus of today's call. We encourage everyone to read today's press releases and the associated materials, which have been filed with the SEC. Additionally, the press release, a recording of this call and our SEC filings can be found under the Investors and News section of our website....
Read the full article on Seeking Alpha
For further details see:
CytomX Therapeutics, Inc. (CTMX) Q1 2024 Earnings Call Transcript